BioSpace News Archive

TELA Bio, Inc., a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, announced Howard N. Langstein, MD, FACS, as Vice President of Medical Affairs and Surgeon Strategy.

NextCure, Inc. (Nasdaq: NXTC) today announced the presentation of new preclinical data on LNCB74, a B7-H4-targeting antibody drug conjugate (ADC) developed in partnership with LigaChem Biosciences (LCB), formerly LegoChem Biosciences, (KOSDAQ: 141080), at the 2024 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.

Eyenovia, Inc., a commercial-stage ophthalmic company, announced its plans for accelerating development of its potential multi-billion dollar product for pediatric progressive myopia and initiated a process to explore strategic alternatives to maximize shareholder value.

Johnson & Johnson announced a new analysis of data from the PIONEER AF-PCI clinical trial demonstrating that XARELTO® was associated with a reduced risk of clinically significant bleeding, and net adverse clinical events or rehospitalization compared to warfarin among both elderly and non-elderly patients with nonvalvular atrial fibrillation undergoing percutaneous coronary intervention, a nonsurgical procedure designed to relieve narrowing or occlusion of the coronary artery.

Labcorp announced today the strategic expansion of its precision oncology portfolio, solidifying its commitment to advancing cancer research and patient care on a global scale.

IdeeLab Biotechnology, a Brazilian company aiming to develop innovations and biological solutions for agriculture, announced that is has entered into an agreement with Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, to join the Ginkgo Technology Network.

Newron Pharmaceuticals S.p.A. presented four posters and two oral presentations at the 2024 Annual Congress of the Schizophrenia International Research Society from 3-7 April in Florence, Italy.

SpineX Inc. has closed recruitment for its clinical trial of its proprietary SCONE™ device. The clinical trial—Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE “CONTINENCE” Clinical Study— began in May 2022.

Satellos Bioscience Inc. announced that management will present at and participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference taking place April 16th and 17th in Toronto.

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is presenting data on the use of INB03, a dominant-negative tumor necrosis factor (TNF) inhibitor of soluble TNF (sTNF) in the treatment of high-risk MUC4 expressing HER2+ and triple negative breast cancer (TNBC).